Annual Accounts Payable
$15.16 M
+$7.26 M+91.82%
December 31, 2023
Summary
- As of February 11, 2025, RPRX annual accounts payable is $15.16 million, with the most recent change of +$7.26 million (+91.82%) on December 31, 2023.
- During the last 3 years, RPRX annual accounts payable has risen by +$4.39 million (+40.74%).
- RPRX annual accounts payable is now at all-time high.
Performance
RPRX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$22.05 M
-$1.36 M-5.81%
September 30, 2024
Summary
- As of February 11, 2025, RPRX quarterly accounts payable is $22.05 million, with the most recent change of -$1.36 million (-5.81%) on September 30, 2024.
- Over the past year, RPRX quarterly accounts payable has increased by +$10.50 million (+90.94%).
- RPRX quarterly accounts payable is now -35.82% below its all-time high of $34.37 million, reached on June 30, 2020.
Performance
RPRX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
RPRX Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +91.8% | +90.9% |
| 3 y3 years | +40.7% | +90.9% |
| 5 y5 years | +238.7% | - |
RPRX Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +169.8% | -5.8% | +292.4% |
| 5 y | 5-year | at high | +169.8% | -35.8% | +292.4% |
| alltime | all time | at high | +238.7% | -35.8% | +292.4% |
Royalty Pharma Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $22.05 M(-5.8%) |
| Jun 2024 | - | $23.42 M(+102.7%) |
| Mar 2024 | - | $11.55 M(-23.8%) |
| Dec 2023 | $15.16 M(+91.8%) | $15.16 M(+11.3%) |
| Sep 2023 | - | $13.63 M(+134.6%) |
| Jun 2023 | - | $5.81 M(-12.7%) |
| Mar 2023 | - | $6.66 M(-15.8%) |
| Dec 2022 | $7.91 M | $7.91 M(-50.9%) |
| Sep 2022 | - | $16.11 M(+32.3%) |
| Jun 2022 | - | $12.18 M(+82.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $6.66 M(+18.5%) |
| Dec 2021 | $5.62 M(-47.8%) | $5.62 M(-38.8%) |
| Sep 2021 | - | $9.19 M(-2.2%) |
| Jun 2021 | - | $9.39 M(+13.6%) |
| Mar 2021 | - | $8.27 M(-23.2%) |
| Dec 2020 | $10.78 M(-3.6%) | $10.78 M(-55.8%) |
| Sep 2020 | - | $24.39 M(-29.0%) |
| Jun 2020 | - | $34.37 M(+65.6%) |
| Mar 2020 | - | $20.75 M(+85.7%) |
| Dec 2019 | $11.18 M(+149.7%) | $11.18 M |
| Dec 2018 | $4.48 M | - |
FAQ
- What is Royalty Pharma annual accounts payable?
- What is the all time high annual accounts payable for Royalty Pharma?
- What is Royalty Pharma annual accounts payable year-on-year change?
- What is Royalty Pharma quarterly accounts payable?
- What is the all time high quarterly accounts payable for Royalty Pharma?
- What is Royalty Pharma quarterly accounts payable year-on-year change?
What is Royalty Pharma annual accounts payable?
The current annual accounts payable of RPRX is $15.16 M
What is the all time high annual accounts payable for Royalty Pharma?
Royalty Pharma all-time high annual accounts payable is $15.16 M
What is Royalty Pharma annual accounts payable year-on-year change?
Over the past year, RPRX annual accounts payable has changed by +$7.26 M (+91.82%)
What is Royalty Pharma quarterly accounts payable?
The current quarterly accounts payable of RPRX is $22.05 M
What is the all time high quarterly accounts payable for Royalty Pharma?
Royalty Pharma all-time high quarterly accounts payable is $34.37 M
What is Royalty Pharma quarterly accounts payable year-on-year change?
Over the past year, RPRX quarterly accounts payable has changed by +$10.50 M (+90.94%)